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What’s already known about the topic? 
• Many uncertainties exist around the management and treatment of alopecia areata 
What does the study add? 
• We present the top 10 uncertainties in alopecia areata management and treatment that are 
important to service users (people with hair loss, their carers and relatives) and healthcare 
professionals 
• These prioritized research uncertainties can be used to guide researchers and funding 
bodies when deciding to invest in alopecia areata research studies 
 
Summary 
Background 
Alopecia areata is a common hair loss disorder that results in patchy to complete hair loss. 
Many uncertainties exist around the most effective treatments for this condition. 
Objectives 
To identify uncertainties in alopecia areata management and treatment that are important to 
both service users (people with hair loss, carers and relatives) and healthcare professionals.  
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Methods 
An alopecia areata priority setting partnership was established between patients, their carers 
and relatives, and healthcare professionals to identify the most important uncertainties in 
alopecia areata. The methodology of the James Lind Alliance was followed to ensure a 
balanced, inclusive and transparent process.   
Results 
In total 2747 treatment uncertainties were submitted by 912 participants, of which 1012 
uncertainties relating to alopecia areata (and variants) were analyzed. Questions were 
combined into “indicative uncertainties” following a structured format. A series of ranking 
exercises further reduced this list to a top 25 that were taken to a final prioritization workshop 
where the top 10 priorities were agreed. 
Conclusions 
We present the top 10 research priorities for alopecia areata to guide researchers and funding 
bodies to support studies important to both patients and clinicians. 
 
Introduction 
Alopecia areata (AA) is an autoimmune hair loss disorder with a reported lifetime risk of 
1.7% 1 that typically presents as patchy areas of hair loss that may involve any scalp or body 
site 2. The extent of hair loss can vary from a small coin-sized patch to complete scalp 
(alopecia totalis) or scalp and body hair loss (alopecia universalis). The skin itself shows no 
evidence of inflammation or scarring. Hair loss in AA is frequently associated with 
psychological distress and may present with symptoms of anxiety, depression or reduction in 
quality of life 3. National guidelines reflect the many uncertainties that exist about optimal 
therapy in AA 4 with the latest Cochrane systematic review published in 2008 concluding 
“there is no good trial evidence that any treatment provides long-term benefit to patients with 
alopecia areata” 5.   
 
The James Lind Alliance (JLA) is a project funded by the National Institute of Health 
Research (NIHR) with support from the Medical Research Council. The aim of the JLA is to 
provide infrastructure and support to patients and clinicians working together to identify the 
most important treatment uncertainties affecting their particular interest, in order to stimulate 
and prioritize future research in that area. The Priority Setting Partnership (PSP) presented 
here was proposed by the British Hair and Nail Society (BHNS) to address treatment 
uncertainties highlighted by systematic reviews, treatment guidelines and clinical experience 
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for alopecia areata (including alopecia totalis / universalis). Working with the JLA and 
funded by the hair loss charity Alopecia UK, this PSP presents priorities for UK hair research 
in a bid to raise the profile of alopecia areata and to open research funding streams to address 
these important uncertainties. 
 
The objectives of the Alopecia Areata PSP were (1) to work with people with AA, their 
partners / parents / carers and healthcare providers to identify uncertainties about AA 
treatment and management, (2) survey the research literature to identify uncertainties and 
research recommendations, (3) agree by consensus a prioritized list of those uncertainties, (4) 
translate these prioritized uncertainties into research questions that can be tested, (5) 
publicize the results of the PSP and process of obtaining them, and (6) take the results to 
research commissioning bodies to be considered for funding. All identified uncertainties from 
this process will be added to the UK Database of Uncertainties about the Effects of 
Treatments (UK-DUETs) (www.library.nhs.uk/duets). 
 
Initially, the plan was to explore uncertainties relating to AA as part of a larger “Hair Loss 
PSP” addressing all types of hair loss within the same process. However, analysis of the 
initial survey revealed that over half of the responses specifically related to alopecia areata 
(including alopecia totalis / universalis). Therefore, the Steering Group (SG) felt it was 
appropriate to separate the analysis at this point into two separate PSP processes that would 
run in parallel yet remain under supervision of the same SG membership. The rationale for 
this change was to prevent one condition dominating the process whilst maximizing 
identification of important uncertainties across all conditions studied. The Hair Loss PSP 
(excluding AA) is reported separately [ref to be inserted]. 
 
Methods 
Following the principles and guidelines set by the JLA, the Alopecia Areata PSP adhered to a 
pre-determined protocol to ensure transparency and inclusivity of all parties within the 
process (www.jla.nihr.ac.uk/priority-setting-partnerships/hair-loss). The SG was established 
in March 2014 by the initial Co-champions (AEM, MH) according to the guidelines of the 
JLA to attempt to ensure balance of all stakeholder groups. The SG comprised four people 
with hair loss representing various patient support groups (JT, JC, KMM, JR), four 
Dermatologists (AEM, MH and 2 further individuals to represent the British Hair and Nail 
Society(PF) and the European Hair Research Society(AGM)), an Academic Psychologist, a 
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registered Trichologist (CM) and a General Practitioner (GP)(RR). A JLA representative 
(SU) provided independent oversight of the PSP and chaired the SG to ensure that members 
adhered to the principles of the James Lind Alliance and that no individuals unduly 
influenced the process. All potential conflicts of interest were declared prospectively.  The 
academic psychologist was unable to continue with the process but submissions represented 
this area well and a psychologist was invited to take part in the final workshop to ensure 
balance. 
The five stages of the PSP process are outlined below and summarized in Figure 1. 
 
Stage 1 – Identification and invitation of potential partners 
Key stakeholders were identified through a process of consultation and peer knowledge, 
building on SG members’ networks and existing JLA’s affiliates. A broad range of 
stakeholder groups were approached and invited to become partners in the PSP process. In 
addition to the BHNS, JLA and Alopecia UK, the following partners engaged in the Alopecia 
Areata PSP: The British Association of Dermatologists (www.bad.org.uk), UK Dermatology 
Clinical Trials Network (UK-DCTN) (www.ukdctn.org), The Institute of Trichologists 
(www.trichologists.org.uk), British Dermatology Nursing Group (www.bdng.org.uk), Skin 
Conditions Campaign Scotland (www.skinconditionscampaignscotland.org), Alopecia Help 
and Advice (Scotland) (alopeciascotland.co.uk), Scottish Alopecia Support Group, My New 
Hair (www.mynewhair.org), British Association of Skin Camouflage (www.skin-
camouflage.net), Changing Faces (www.changingfaces.org.uk), European Hair Research 
Society (www.ehrs.org) and ‘Look Good, Feel Better’ (www.lookgoodfeelbetter.co.uk). 
 
Stage 2 – Invitation to submit uncertainties 
Survey 1 took place from 8th September 2014 – 31st October 2014 and was open to any one 
residing in the UK The initial invitation to submit uncertainties involved an online survey 
(Survey Monkey™) accessed through the Alopecia UK website 
(www.alopeciaonline.org.uk). In addition, paper surveys were available on request and were 
also distributed at key events. Through engagement with the various partner organizations, 
local advertisement and via social media, a range of people with different hair loss 
conditions, their carers and relatives, and healthcare professions were targeted.  
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Uncertainties were invited by asking the following question: “Do you have questions about 
prevention, diagnosis or treatment of hair loss that need to be answered by research?”. 
Participants were permitted to submit as many or as few questions as they wished, and these 
could relate to one or more hair loss conditions. The survey contained a participant 
information sheet to provide background to the process and survey text was designed to be 
easy to understand and provide all the relevant information for self-completion. Submitting 
the completed survey was considered as consent to participate in the PSP process and publish 
the (anonymized) uncertainties generated on UK-DUETs. 
 
Stage 3 - Collation 
The aim of this stage was to review all the submitted questions, exclude questions outside the 
remit of the PSP and generate “indicative uncertainties” (i.e. a collation of similar questions 
into one clear, understandable question presented in a standard format). Non-questions (e.g. 
statements or comments without questions within) and questions not directly relating to a hair 
loss disorder were excluded. Questions that could be resolved with reference to existing 
research evidence (so called "unknown knowns") were identified from existing sources of 
information, in particular systematic reviews, evidence based guidelines and prospective trial 
registries. Exclusion of questions or comments outside of the remit of the Alopecia Areata 
PSP were made by consensus within the SG. Uncertainties which were not adequately 
addressed by previous research were collated and will be entered into a hair loss section 
within UK DUETs (www.library.nhs.uk/duets). 
 
Stage 4 – Ranking of treatment uncertainties 
The aim of this stage was to generate a short-list of indicative uncertainties deemed by both 
people with AA and healthcare professionals to be important. To reduce the large number of 
indicative uncertainties generated in stage 3 to a reasonable number for ranking, an “interim 
list” was created using criteria agreed by the SG. These criteria were designed to identify 
which questions were asked most frequently, with weight given to questions asked by more 
than one person and questions asked by both patients and healthcare professionals 
independently. This process generated a list of 51 questions to go forward to the second 
survey.  
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
The second online ranking survey was completed by previous participants, by invitation, to 
further refine the interim list into a short-list of 25 uncertainties to take to the final workshop. 
500 participants from the initial survey had provided contact details and were invited to 
participate in the interim ranking. 87 participants (17.4%) returned responses for the second 
survey. Participants were invited to choose up to ten uncertainties from the interim list that 
they considered to be most important but were not asked to prioritise them. The responses 
obtained were used to rank the uncertainties by number of votes. The priorities of the 
different groups of responders were listed separately and compared. 
 
Stage 5- Final workshop 
The final workshop took place on 6th November 2015 at Willan House in London. The aim of 
this stage was to prioritize, through consensus, the most popular uncertainties relating to the 
management of AA from the 25 uncertainties generated by the interim process. Attendance at 
the final workshops was designed to represent a balanced distribution of interested parties 
and ensuring a good representation from patients (7/19) and healthcare professionals (5 
Dermatologists, 3 Trichologists, 3 GPs and a Psychologist). Those attending the priority 
setting workshop were asked to complete a declaration of interests, including disclosure of 
relationships with for-profit organizations.  The final workshop was facilitated by three 
independent JLA facilitators to ensure fairness, transparency and accountability and to ensure 
no unfair influence by any individual. Using nominal group technique, 100% consensus was 
achieved through ranking and plenary sessions, eventually generating the top ten research 
priorities. During breakout groups, the uncertainties were ranked and allocated a numerical 
position. The ‘scores’, as the sum of the numerical positions in each break out group, were 
used to rank the questions for the whole group plenary discussion. 3 breakout sessions and 3 
whole group plenaries were required to achieve consensus. 
Results 
The initial survey was completed by 912 participants generating 2747 responses, 83% from 
patients, carers and relatives and 13% healthcare professionals (Figure 2). After removal of 
non-questions and those deemed “out of scope” (e.g. non-questions / statements / not  directly 
relating to hair loss, etc.) 1823 uncertainties remained of which 1015 related to alopecia 
areata. 
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Twenty of the 1015 submitted uncertainties could be answered from available evidence and 
so were excluded. Indicative uncertainties were generated by combining similar questions 
and standardized using “PICO” (Population Intervention Comparator Outcome) formatting. 
This process generated an interim list of 170 uncertainties that was further reduced by 
ranking questions based on the number of submissions, with priority given to those questions 
posed by both patients and healthcare professionals. The top 51 uncertainties were taken 
forward to the second ranking survey that ran from 22nd September 2015 to 4th October 2015. 
The top 25 uncertainties were taken to the final workshop on 6th November 2015 to select the 
“Top 10” research uncertainties by consensus (Table 1). 
 
Conclusion 
Here we present an overview of this PSP that has demonstrated a number of uncertainties 
relating to the management and treatment of AA. By adhering to the JLA ethos of inclusivity 
and transparency, and using a combination of online surveys and face-to-face workshops, we 
can feel confident that the outcomes generated here accurately reflects the consensus view of 
both service users (people with AA, carers and relatives) and healthcare professionals in 
determining future priorities for AA research.  
 
Feedback from participants in the final workshop revealed that the opportunity to discuss the 
questions allowed different viewpoints to be aired, identified positions that they had not 
previously considered and gave rise to a more balanced appraisal of the priorities. Thus, the 
final top 10 did not exactly reflect the ranking (performed independently) from the second 
survey. Discussion on position of ranking was frequently influenced by the other questions 
presented, with certain questions relegated in priority if they were deemed to be covered by 
other uncertainties more highly ranked in the process.  Although deliverability of the research 
was considered in appraising each question, it was acknowledged that the questions broadly 
represented a theme for research that would require refinement before being developed into a 
completed research question. A workshop has been planned to further progress these research 
uncertainties to fully formed research questions and to develop vignettes. 
 
Interestingly, a significant proportion of the originally submitted questions did not represent 
an uncertainty at all, but reflected a lack of information around treatment options and service 
provision. Recurring themes included availability of services, treatment strategies, wig 
provision and the low priority given to hair loss in the NHS. Striking was the frequency of 
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comments relating to experiences of patients accessing medical services, particularly seeing 
GPs, with many describing a perceived lack of knowledge, reluctance to refer and in some 
cases a lack of compassion when dealing with their distressing problem. Thus, a greater 
awareness and education of GPs / healthcare professionals around hair loss was suggested to 
highlight and address the (openly acknowledged) inadequate dermatology training currently 
received in the UK by many medical students and GP trainees in the field of hair loss. 
 
Some problems were encountered during the process mainly around data handling and the 
large number of uncertainties originally submitted (2747 questions). By necessity a “Data 
team” was set up to process these results. However, some inconsistency in taxonomy 
allocation to categorize questions occurred that may have been overcome by just one or two 
people only handling the results, although this would have significantly prolonged the 
process in time and costs. Another area of difficulty was around engagement of key 
stakeholders. In general smaller and specialized organizations were keen to become partners 
in the process. However, some larger organizations were reluctant to commit to partnership 
but agreed to advertise the PSP to their members, whereas other groups refused to engage 
completely. These decisions appeared to relate to the inability of such large organizations to 
commit to these types of projects for which they are frequently approached to support. As the 
number of PSPs in all fields are likely to increase, with many groups anticipated to want 
engagement with similar stakeholders each time it was felt by the SG that the JLA should 
consider setting up a higher level agreement with the main stakeholder groups (particularly 
the Royal Colleges and Specialist Associations) to provide a minimum level of commitment 
for all future JLA-supported PSP processes. 
 
We present an overview of the alopecia areata PSP process, including pitfalls encountered 
along the way. By presenting the top 10 uncertainties in AA identified as important by both 
patients and clinicians we hope to raise awareness of this disorder and influence research 
priorities in the future. These outcomes will be put forward to  researchers and funding bodies 
with the ultimate aim of securing meaningful research funds to address these important 
issues. 
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Figure legends 
 
Figure 1- Overview of the Alopecia Areata Priority Setting Partnership process  
 
Figure 2- Division of participants of initial survey by category (n= 912)  
 
Table 1- Top 10 research uncertainties for alopecia areata prioritized by consensus. 
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Table 1- Top 10 research uncertainties for alopecia areata prioritized by consensus. 
 
Rank  Uncertainty  
1  What are the causes of alopecia areata? For example- medications, medical problems, 
lifestyle, vaccinations.  
2  Are immunosuppressant therapies (for example- methotrexate, mycophenolate mofetil) 
better than placebo in the treatment of alopecia areata?  
3  In alopecia areata, are biological therapies (including janus kinase (JAK) inhibitors and 
anti-cytokine therapies) more effective than placebo in causing hair regrowth?  
4  Are psychological interventions helpful in alopecia areata?  
5  Can progression of alopecia areata be prevented by early diagnosis and treatment?  
6  Do certain foods, vitamins or nutritional supplements improve hair re-growth in 
alopecia areata?  
7  What can be learnt about alopecia areata from other autoimmune conditions?  
8  In whom does alopecia areata hair loss progress and why?  
9  Do any treatments have a long-term therapeutic benefit in alopecia areata?  
10  How effective are alternative therapies in alopecia areata? 
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Stage 1: Identification and Invitation of Potential Partners 
Stage 2: Invitation to Submit Uncertainties (Initial survey)
912 responders with 2747 responses
Stage 3: Collation
1015 uncertainties for alopecia areata
Stage 4: Ranking of Treatment Uncertainties
87 responders
Stage 5: Final Workshop
19 participants
 
 
Figure 2- Division of participants in initial survey by category (n= 912)
 
